Alexza Pharmaceuticals (ALXA) suffers from a double whammy after the close, simultaneously...


Alexza Pharmaceuticals (ALXA) suffers from a double whammy after the close, simultaneously missing on its Q3 results and disclosing that E.U. regulators aren't going to approve Adasuve due to major objections. In September, the company received the Day 180 List of Outstanding Issues from European regulators which questions whether the data supports the drug's broad indication as submitted, and if the dosage requirements to achieve any benefit warrant the risk. Shares -6% AH.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs